Literature DB >> 22122284

Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?

Yu Wang1, Caroline G L Lee.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, characterized by high mortality rate and poor prognosis. Our understanding of the HCC pathology is still very much fragmented and little progress has been made to improve the clinical outcome of HCC patients. While recently discovered microRNA deregulation in HCC has added to the complexity of our understanding of HCC, it has also presented promising novel approaches to understand, diagnose and treat HCC. Here, we highlight one miRNA, miR-224, which has been more consistently reported to be upregulated in HCC than other miRNAs. We will discuss the validated and predicted functional roles of this miRNA in HCC, speculate on the possible mechanism for its upregulation in HCC and explore the potential of miR-224 as an exciting novel biomarker for the early detection of liver malignancies as well as a novel therapeutic target for HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122284     DOI: 10.2217/epi.11.5

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  25 in total

1.  The MicroRNA-224 Inhibitor Prevents Neuronal Apoptosis via Targeting Spastic Paraplegia 7 After Cerebral Ischemia.

Authors:  Feng Fu; Dingfeng Wu; Chao Qian
Journal:  J Mol Neurosci       Date:  2016-05-10       Impact factor: 3.444

2.  Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma.

Authors:  Hao Gu; Xiaodong Guo; Lin Zou; Haiyan Zhu; Jinhui Zhang
Journal:  Mol Cell Biochem       Date:  2013-01-06       Impact factor: 3.396

3.  MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.

Authors:  Yu Wang; Han Chong Toh; Pierce Chow; Alexander Y F Chung; David J Meyers; Philip A Cole; London L P J Ooi; Caroline G L Lee
Journal:  FASEB J       Date:  2012-03-29       Impact factor: 5.191

4.  Unique microRNA alterations in hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice.

Authors:  Haruhiro Yamashita; Sailesh Surapureddi; Ramesh C Kovi; Sachin Bhusari; Thai Vu Ton; Jian-Liang Li; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; Cynthia V Rider; Mark J Hoenerhoff; Robert C Sills; Arun R Pandiri
Journal:  Arch Toxicol       Date:  2020-04-18       Impact factor: 5.153

5.  Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma.

Authors:  Xiaomei Zhang; Yunsheng Yang; Xuefeng Liu; James G Herman; Malcolm V Brock; Julien D F Licchesi; Wen Yue; Xuetao Pei; Mingzhou Guo
Journal:  Epigenetics       Date:  2013-02-28       Impact factor: 4.528

Review 6.  MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer.

Authors:  Rui Yi; Yao Li; Fei-Liang Wang; Gang Miao; Ruo-Mei Qi; Yan-Yang Zhao
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

7.  MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival.

Authors:  Yu Wang; Jianwei Ren; Yun Gao; Joel Z I Ma; Han Chong Toh; Pierce Chow; Alexander Y F Chung; London L P J Ooi; Caroline G L Lee
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

8.  Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas.

Authors:  Liping Liu; Kun Chen; Jueheng Wu; Ling Shi; Bo Hu; Shiyuan Cheng; Mengfeng Li; Libing Song
Journal:  Clin Cancer Res       Date:  2013-05-21       Impact factor: 12.531

9.  Upregulation of microRNA-224 confers a poor prognosis in glioma patients.

Authors:  S Lu; S Wang; S Geng; S Ma; Z Liang; B Jiao
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

10.  Transcriptional and translational regulation of C/EBPβ-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1α proteins at the early and late stages of liver cancer.

Authors:  Jingling Jin; Polina Iakova; Yanjun Jiang; Kyle Lewis; Emily Sullivan; Nicole Jawanmardi; Lawrence Donehower; Lubov Timchenko; Nikolai A Timchenko
Journal:  J Biol Chem       Date:  2013-04-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.